Alivus Life Sciences reports Q4 FY25 PAT at Rs. 141.86 Cr

Alivus Life Sciences reports Q4 FY25 PAT at Rs. 141.86 Cr

By: IPP Bureau

Last updated : May 18, 2025 11:17 am



The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025


Alivus Life Sciences, formerly known as Glenmark Life Sciences Ltd, has reported Standalone financial results for the period ended March 31, 2025.

Alivus Life Sciences has posted net profit of Rs. 141.86 crores for the period ended March 31, 2025 as against net profit of Rs. 136.96 crores for the period ended December 31, 2024. The company posted net profit of Rs. 97.93 crores for the period ended March 31, 2024.

Alivus Life Sciences has reported total income of Rs. 659.63 crores during the period ended March 31, 2025 as compared to Rs. 652.30 crores during the period ended December 31, 2024. The company reported total income of Rs. 539.728 crores during the period ended March 31, 2024.

For the Financial Year ended March 31, 2025, Alivus Life Sciences has reported total income of Rs. 2,421.45 crores as compared to Rs. 2,295.25 crores during the Financial Year ended March 31, 2024.

The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025 as against net profit of Rs. 470.88 crores for the Financial Year ended March 31, 2024.

Alivus Life Sciences Glenmark Life Sciences Ltd

First Published : May 18, 2025 12:00 am